Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 85509-1443

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 85509-1443). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Phoenix Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (8550914433)

Label for Rabeprazole Sodium delayed-release tablets, 20 mg strength. The label indicates a package of 30 tablets, marked Rx only. Manufactured by Alkem Laboratories Ltd. and repackaged by PHOENIX RX LLC, Hatboro, PA. Storage instructions note protection from moisture and temperature control. The NDC number 85509-1443 is prominently displayed, along with barcode and QR code for package insert.*

FDA Label Image

Rabe-str (Rabe Str)

Chemical structure diagram of rabeprazole sodium showing its molecular components and bonds, including a sodium atom and organic moieties characteristic of the active ingredient.*

FDA Label Image

Rabe-str2 (Rabe Str2)

A line graph comparing mean heartburn scores over a 28-day study period among three groups: placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg. The x-axis shows study days from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). Scores decrease after day 0, with the Rabeprazole 20 mg group showing the most significant reduction.*

FDA Label Image

Rabe-str3 (Rabe Str3)

A line graph comparing mean heartburn scores over a 28-day study period for Rabeprazole Sodium 20 mg tablets versus placebo. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores on a scale from 0 (none) to 4 (very severe). Two lines indicate scores for placebo and Rabeprazole 20 mg groups, showing changes in symptoms over time.*

FDA Label Image

Rabe-str4 (Rabe Str4)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group and a Rabeprazole Sodium 20 mg group. The x-axis represents study days, from 14 days before treatment to 28 days after, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph shows lower heartburn scores in the Rabeprazole group compared to placebo after treatment starts.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.